Published in
Elsevier, The Lancet Oncology, 13(15), p. 1451-1459, 2014
DOI: 10.1016/s1470-2045(14)71017-4
Links
Tools
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial
Journal article published in 2014 by
Glen A. Kennedy,
Antiopi Varelias,
Slavica Vuckovic,
Laetitia Le Texier,
Kate H. Gartlan 
,
Ping Zhang,
Gethin Thomas,
Lisa Anderson,
Glen Boyle,
Nicole Cloonan,
Justine Leach,
Elise Sturgeon,
Judy Avery,
Stuart D. Olver,
Mary Lor
and other authors.
,
Ping Zhang,
Gethin Thomas,
Lisa Anderson,
Glen Boyle,
Nicole Cloonan,
Justine Leach,
Elise Sturgeon,
Judy Avery,
Stuart D. Olver,
Mary Lor
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 